MA29812B1 - N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides cycliques, procedes pour leur preparation et leur utilisation en tant que substances pharmaceutiques - Google Patents
N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides cycliques, procedes pour leur preparation et leur utilisation en tant que substances pharmaceutiquesInfo
- Publication number
- MA29812B1 MA29812B1 MA30790A MA30790A MA29812B1 MA 29812 B1 MA29812 B1 MA 29812B1 MA 30790 A MA30790 A MA 30790A MA 30790 A MA30790 A MA 30790A MA 29812 B1 MA29812 B1 MA 29812B1
- Authority
- MA
- Morocco
- Prior art keywords
- thiadiazol
- processes
- preparation
- cyclic
- benzene sulfonamides
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 229940124530 sulfonamide Drugs 0.000 title abstract 2
- 239000000126 substance Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004129 fatty acid metabolism Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE LES N-[1,3,4]-THIADIAZOL-2-YL-BENZÈNE SULFONAMIDES CYCLIQUES AINSI QUE LEURS SELS PHYSIOLOGIQUEMENT ACCEPTABLES ET LEURS DÉRIVÉS PHYSIOLOGIQUEMENT FONCTIONNELS PRÉSENTANT UNE ACTIVITÉ AGONISTE VIS-À-VIS DE PPARDELTA OR PPARDELTA ET PPARGAMMA. L¿INVENTION CONCERNE DES COMPOSÉS DE FORMULE (I), LES RADICAUX ÉTANT TELS QUE DÉFINIS, AINSI QUE LEURS SELS PHYSIOLOGIQUEMENT ACCEPTABLES ET DES PROCÉDÉS POUR LEUR PRÉPARATION. LES COMPOSÉS CONVIENNENT POUR LE TRAITEMENT ET/OU LA PRÉVENTION DES PATHOLOGIES LIÉES AU MÉTABOLISME DES ACIDES GRAS ET À L¿UTILISATION DU GLUCOSE, AINSI QUE DES PATHOLOGIES LIÉES À LA RÉSISTANCE À L¿INSULINE ET À LA DÉMYÉLINISATION ET D¿AUTRES MALADIES NEURODÉGÉNÉRATIVES DU SYSTÈME NERVEUX CENTRAL ET PÉRIPHÉRIQUE.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05021785 | 2005-10-06 | ||
| PCT/EP2006/009299 WO2007039173A1 (fr) | 2005-10-06 | 2006-09-26 | N-[1,3,4]-thiadiazol-2-yl-benzène sulfonamides cycliques, procédés pour leur préparation et leur utilisation en tant que substances pharmaceutiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA29812B1 true MA29812B1 (fr) | 2008-09-01 |
Family
ID=45218083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA30790A MA29812B1 (fr) | 2005-10-06 | 2008-03-31 | N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides cycliques, procedes pour leur preparation et leur utilisation en tant que substances pharmaceutiques |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7683181B2 (fr) |
| EP (1) | EP1937659B1 (fr) |
| JP (1) | JP2009510145A (fr) |
| KR (1) | KR20080050472A (fr) |
| CN (1) | CN101282952A (fr) |
| AR (1) | AR056562A1 (fr) |
| AT (1) | ATE487706T1 (fr) |
| AU (1) | AU2006299087A1 (fr) |
| BR (1) | BRPI0616886A2 (fr) |
| CA (1) | CA2624326A1 (fr) |
| DE (1) | DE602006018172D1 (fr) |
| IL (1) | IL190464A0 (fr) |
| MA (1) | MA29812B1 (fr) |
| NO (1) | NO20081675L (fr) |
| NZ (1) | NZ567205A (fr) |
| RU (1) | RU2008113208A (fr) |
| UY (1) | UY29847A1 (fr) |
| WO (1) | WO2007039173A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009043784A1 (fr) * | 2007-10-04 | 2009-04-09 | F. Hoffmann-La Roche Ag | Dérivés de cyclopropyl aryl amides et leurs utilisations |
| KR20100101165A (ko) | 2007-12-26 | 2010-09-16 | 사노피-아벤티스 | 사이클릭 피리딜ｎ（１,３,４）티아디아졸２일-벤젠 설폰아미드, 이들의 제조방법 및 약제로서의 이들의 용도 |
| MX2010011258A (es) | 2008-04-14 | 2011-06-20 | Univ Texas | Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos. |
| US9045445B2 (en) | 2010-06-04 | 2015-06-02 | Albany Molecular Research, Inc. | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
| WO2014093988A2 (fr) | 2012-12-14 | 2014-06-19 | Phusis Therapeutics, Inc. | Procédés et compositions pour l'inhibition de cnksr1 |
| US10227356B2 (en) | 2015-04-20 | 2019-03-12 | Phusis Therapeutics, Inc. | Compounds, compositions and methods for inhibiting CNKSR1 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA02010651A (es) * | 2000-04-28 | 2003-03-10 | Sankyo Co | Moduladores de receptor activado de proliferador de peroxisoma-gamma. |
-
2006
- 2006-09-26 AT AT06805858T patent/ATE487706T1/de not_active IP Right Cessation
- 2006-09-26 CA CA002624326A patent/CA2624326A1/fr not_active Abandoned
- 2006-09-26 BR BRPI0616886-8A patent/BRPI0616886A2/pt not_active IP Right Cessation
- 2006-09-26 WO PCT/EP2006/009299 patent/WO2007039173A1/fr not_active Ceased
- 2006-09-26 EP EP06805858A patent/EP1937659B1/fr active Active
- 2006-09-26 JP JP2008533905A patent/JP2009510145A/ja not_active Abandoned
- 2006-09-26 KR KR1020087008276A patent/KR20080050472A/ko not_active Withdrawn
- 2006-09-26 NZ NZ567205A patent/NZ567205A/en not_active IP Right Cessation
- 2006-09-26 RU RU2008113208/04A patent/RU2008113208A/ru not_active Application Discontinuation
- 2006-09-26 AU AU2006299087A patent/AU2006299087A1/en not_active Abandoned
- 2006-09-26 CN CNA2006800370657A patent/CN101282952A/zh active Pending
- 2006-09-26 DE DE602006018172T patent/DE602006018172D1/de active Active
- 2006-10-04 AR ARP060104360A patent/AR056562A1/es unknown
- 2006-10-06 UY UY29847A patent/UY29847A1/es not_active Application Discontinuation
-
2008
- 2008-03-26 IL IL190464A patent/IL190464A0/en unknown
- 2008-03-31 MA MA30790A patent/MA29812B1/fr unknown
- 2008-04-04 US US12/062,753 patent/US7683181B2/en active Active
- 2008-04-04 NO NO20081675A patent/NO20081675L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2008113208A (ru) | 2009-10-10 |
| IL190464A0 (en) | 2008-11-03 |
| UY29847A1 (es) | 2007-05-31 |
| US20080280959A1 (en) | 2008-11-13 |
| AU2006299087A1 (en) | 2007-04-12 |
| EP1937659A1 (fr) | 2008-07-02 |
| BRPI0616886A2 (pt) | 2011-07-05 |
| CN101282952A (zh) | 2008-10-08 |
| NO20081675L (no) | 2008-04-23 |
| EP1937659B1 (fr) | 2010-11-10 |
| US7683181B2 (en) | 2010-03-23 |
| CA2624326A1 (fr) | 2007-04-12 |
| DE602006018172D1 (de) | 2010-12-23 |
| WO2007039173A1 (fr) | 2007-04-12 |
| NZ567205A (en) | 2010-05-28 |
| KR20080050472A (ko) | 2008-06-05 |
| JP2009510145A (ja) | 2009-03-12 |
| AR056562A1 (es) | 2007-10-10 |
| ATE487706T1 (de) | 2010-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA29810B1 (fr) | 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzènesulfonamides, procédés pour leur préparation et leur utilisation en tant que produits pharmaceutiques | |
| MA29804B1 (fr) | Derives de phenyl-et pyridyl-1,2,4-oxadiazolone renfermant un groupe phenyle, procedes pour leur preparation et leur utilisation en tant qu'agents pharmaceutiques | |
| MA30782B1 (fr) | Amides substitues, procede de production et d'utilisation desdits amides | |
| MA29805B1 (fr) | Derives de phenyl-1.2.4-oxadiazolone, leurs procedes de preparation et leur utilisation comme produits pharmaceutiques | |
| RU2498988C2 (ru) | Ингибиторы активности протеинтирозинкиназы | |
| MA33450B1 (fr) | Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques | |
| MA30084B1 (fr) | Triazolopyridazines en tant que modulateurs de la tyrosine kinase | |
| MA35874B1 (fr) | Dérivés d'amide cycliques à utiliser en tant qu'inhibiteurs de 11-bêta-hydroxystéroïde déshydrogénase et utilisations de ceux-ci | |
| MA30906B1 (fr) | Composes et compositions en tant quinhibiteurs des proteines kinases | |
| MA30333B1 (fr) | Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete. | |
| MA32120B1 (fr) | Nouveaux composes chimiques | |
| MA34898B1 (fr) | Nouveaux dérivés hétérocycliques et leur utilisation dans le traitement de troubles neurologiques | |
| MA30696B1 (fr) | Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique | |
| MA30999B1 (fr) | Composés. | |
| MA30421B1 (fr) | Pyrrolidinones substituees par un piperidinyle en tant qu'inhibiteurs de la 11-bêta-hydroxysteroïde deshydrogenase 1 | |
| MA30911B1 (fr) | Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine | |
| MA30089B1 (fr) | (arylsulfonyl)-pyrasolopiperidines | |
| MA30073B1 (fr) | Derives de piperidine 3,5-substitues en tant qu'inhibiteurs de renine | |
| MA30916B1 (fr) | Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine | |
| MA30440B1 (fr) | NOUVEAUX MEDICAMENTS ANTIARYTHMIQUES ET CONTRE LA DEFAILLANCE CARDIAQUE CIBLANT LA FUITE DANS UN RECEPTEUR DE LA PYANODINE (RyR2). | |
| MA27097A1 (fr) | Aza-arylpiperazines | |
| EP2091328A4 (fr) | Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer | |
| MX2010006647A (es) | Piridil-n-[1,3,4]-tiadiazol-2-il-bencenosulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticos. | |
| Fernandes et al. | Phthalimide as a versatile pharmacophore scaffold: Unlocking its diverse biological activities | |
| MA32108B1 (fr) | Derives d'indazole |